TCM
RNAZ icon

Tang Capital Management’s TransCode Therapeutics RNAZ Stock Holding History

Tang Capital Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2
Closed -$42.2K – 131
2023
Q3 		$42.2K Buy
+2
New +$126K 0.01% 106

Other funds holding RNAZ

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tang Capital Management's RNAZ Position: Q4 2023 in Review

Tang Capital Management sold out of TransCode Therapeutics (RNAZ) in Q4 2023, closing a stake of 2 shares — an estimated $42.2K sold.

Tang Capital Management first reported a position in RNAZ in Q3 2023 and held it in 1 quarter. The position peaked at $42.2K in Q3 2023. 5 funds tracked by Wall St. Rank hold RNAZ as of Q4 2023.

  • Tang Capital Management reported no remaining TransCode Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Tang Capital Management sold 2 TransCode Therapeutics shares in Q4 2023, an estimated $42.2K.
  • Tang Capital Management first reported a position in TransCode Therapeutics in Q3 2023 and held it in 1 quarter.
  • Tang Capital Management's TransCode Therapeutics position peaked at $42.2K in Q3 2023.
  • 5 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2023.

Based on Tang Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.